journal
MENU ▼
Read by QxMD icon Read
search

European Journal of Drug Metabolism and Pharmacokinetics

journal
https://www.readbyqxmd.com/read/29956215/pharmacokinetics-of-tramadol-and-celecoxib-in-japanese-and-caucasian-subjects-following-administration-of-co-crystal-of-tramadol-celecoxib-ctc-a-randomised-open-label-study
#1
Helen Dooner, Gill Mundin, Sabine Mersmann, Carla Bennett, Ulrike Lorch, Mercedes Encabo, Marisol Escriche, Gregorio Encina, Kevin Smith
BACKGROUND AND OBJECTIVES: Co-Crystal of Tramadol-Celecoxib (CTC) is a first-in-class active pharmaceutical ingredient (API-API) co-crystal of rac-tramadol.HCl and celecoxib in a 1:1 molecular ratio (100 mg CTC: 44 mg rac-tramadol.HCl and 56 mg celecoxib). Tramadol and celecoxib pharmacokinetics are modified after CTC administration versus administration of reference products. This randomised, open-label, crossover, phase 1 study assessed CTC pharmacokinetics, dose proportionality, safety and tolerability in Japanese and Caucasian subjects...
June 28, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29946921/model-informed-approaches-for-alternative-aripiprazole-dosing-regimens-and-missed-dose-management-towards-better-adherence-to-antipsychotic-pharmacotherapy
#2
LETTER
Jun-Yi Wu, Guo Yu, Guo-Fu Li
No abstract text is available yet for this article.
June 26, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29943105/application-of-a-volumetric-absorptive-microsampling-device-to-a-pharmacokinetic-study-of-tacrolimus-in-rats-comparison-with-wet-blood-and-plasma
#3
Kenji Kita, Kenichi Noritake, Yuji Mano
BACKGROUND AND OBJECTIVES: Volumetric absorptive microsampling (VAMS) devices are useful for sampling a smaller volume of blood from rodents in the preclinical setting. In the present study, we evaluated the proof of concept of a VAMS device by comparing the pharmacokinetic data of tacrolimus in rats among dried blood in VAMS, wet blood, and plasma. METHODS: Tacrolimus was administered orally, to rats, at a dose of 10 mg/kg. Only 10 μL aliquots of blood were absorbed by VAMS devices at designated time points...
June 25, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29915955/population-pharmacokinetic-modeling-of-remifentanil-in-infants-with-unrepaired-tetralogy-of-fallot
#4
Jing Chang, Yang Shen, Yue Huang, Ying Sun, Mei-Hua Cai, Jing Niu, Li-Ming Zhang, Ji-Jian Zheng, Ma-Zhong Zhang
BACKGROUND: Although there is literature suggesting that pathophysiologic changes in children with congenital heart disease alter the pharmacokinetics of anesthetics and may result in dosage adjustment, limited information exists regarding the pharmacokinetics of remifentanil in infants with unrepaired tetralogy of Fallot (TOF). The objectives of the current analysis were to characterize the population pharmacokinetics of remifentanil in infants, and to evaluate the effects of TOF on remifentanil's pharmacokinetics...
June 19, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29909549/pharmacokinetics-of-ombitasvir-paritaprevir-ritonavir-and-dasabuvir-in-healthy-chinese-subjects-and-hcv-gt1b-infected-chinese-south-korean-and-taiwanese-patients
#5
Jiuhong Zha, Bifeng Ding, Haoyu Wang, Weihan Zhao, Chen Yu, Katia Alves, Niloufar Mobashery, Yan Luo, Rajeev M Menon
BACKGROUND/PURPOSE: The 3 direct-acting antiviral (3D) regimen of ombitasvir/paritaprevir/ritonavir plus dasabuvir has recently been approved in several Asian geographic regions for the treatment of hepatitis C virus (HCV) genotype (GT) 1 infection. The pharmacokinetics of the components of the 3D regimen with or without ribavirin were evaluated in healthy Chinese subjects and HCV GT1b-infected Chinese, South Korean, and Taiwanese patients, with or without cirrhosis, to determine how the drug exposures in Asian populations compare with historical data in Western populations...
June 16, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29948848/bayesian-population-pharmacokinetic-modeling-of-eltrombopag-in-chronic-hepatitis-c-patients
#6
Mohammad I Saleh, Suhad Bani Melhim, Hanguin M Al-Ramadhani, Sameh Alzubiedi
BACKGROUND AND OBJECTIVES: Eltrombopag is a thrombopoietic growth factor that is approved for the treatment of thrombocytopenia in chronic hepatitis C virus (HCV) patients. We aimed to describe eltrombopag population pharmacokinetics in hepatitis C patients. Bayesian statistical approach will be applied to screen for patients' characteristics associated with eltrombopag pharmacokinetic parameters. METHODS: A population pharmacokinetic analysis was conducted using WinBUGS version 1...
June 14, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29943125/population-pharmacokinetic-analysis-and-model-based-simulations-of-aripiprazole-for-a-1-day-initiation-regimen-for-the-long-acting-antipsychotic-aripiprazole-lauroxil
#7
Marjie L Hard, Angela Y Wehr, Brian M Sadler, Richard J Mills, Lisa von Moltke
BACKGROUND AND OBJECTIVES: Aripiprazole lauroxil (AL), a long-acting injectable antipsychotic for the treatment of schizophrenia, requires 21 days of oral aripiprazole supplementation upon initiation (21-day initiation regimen). An alternative 1-day initiation regimen utilizing a nano-crystalline milled dispersion of AL (ALNCD ) plus a single 30 mg oral aripiprazole dose achieved aripiprazole concentrations associated with therapeutic doses of aripiprazole in the same time frame as the 21-day initiation regimen when starting AL (441 or 882 mg)...
June 11, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29876844/nutritional-status-differentially-alters-cytochrome-p450-3a4-cyp3a4-and-uridine-5-diphospho-glucuronosyltransferase-ugt-mediated-drug-metabolism-effect-of-short-term-fasting-and-high-fat-diet-on-midazolam-metabolism
#8
Laureen A Lammers, Roos Achterbergh, Johannes A Romijn, Ron A A Mathôt
BACKGROUND AND OBJECTIVES: Previous studies have shown that nutritional status can alter drug metabolism which may result in treatment failure or untoward side effects. This study assesses the effect of two nutritional conditions, short-term fasting, and a short-term high fat diet (HFD) on cytochrome P450 3A4 (CYP3A4) and uridine 5'-diphospho-glucuronosyltransferase (UGT) mediated drug metabolism by studying the pharmacokinetics of midazolam and its main metabolites. METHODS: In a randomized-controlled cross-over trial, nine healthy subjects received a single intravenous administration of 0...
June 6, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29858835/potential-influence-of-centrally-acting-herbal-drugs-on-transporters-at-the-blood-cerebrospinal-fluid-barrier-and-blood-brain-barrier
#9
REVIEW
Lilian W Kibathi, SoHyun Bae, Scott R Penzak, Parag Kumar
Complementary and alternative medications (CAM) with known or suspected pharmacologic activity in the central nervous system (CNS) are common. These herbal preparations may cause clinically significant drug-drug interactions (DDIs) when coadministered with medications that act in the CNS. This can result in negative outcomes such as toxicity or loss of efficacy. Most drug interaction reports with CAM focus on cytochrome P450 (CYP) modulation. However, drug interactions between CAM and conventional medications may occur via mechanisms other than CYP inhibition or induction; in particular, modulation of drug transport proteins represents an important mechanism by which such interactions may occur...
June 1, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29785610/evaluation-of-strategies-for-the-assessment-of-drug-drug-interactions-involving-cytochrome-p450-enzymes
#10
Jelle Reinen, Martijn Smit, Mira Wenker
BACKGROUND AND OBJECTIVES: Drug-drug interactions (DDIs) can occur when one drug alters the metabolism of another drug. Drug metabolism mediated by cytochrome P450 enzymes (CYPs) is responsible for the majority of metabolism of known drugs and inhibition of CYP enzymes is a well-known cause of DDIs. In the current study, the use of various human liver microsomes (HLM)-based methods to determine occurrence of CYP-mediated metabolism-dependent inhibition (MDI) and possible follow-up studies were evaluated...
May 21, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29785609/evaluation-of-focei-and-saem-estimation-methods-in-population-pharmacokinetic-analysis-using-nonmem-%C3%A2-across-rich-medium-and-sparse-sampling-data
#11
Waroonrat Sukarnjanaset, Thitima Wattanavijitkul, Sutep Jarurattanasirikul
BACKGROUND AND OBJECTIVES: First-order conditional estimation with interaction (FOCEI) is one of the most commonly used estimation methods in nonlinear mixed effects modeling, while the stochastic approximation expectation maximization (SAEM) is the newer estimation algorithm. This work aimed to compare the performance of FOCEI and SAEM methods when using NONMEM® with the classical one- and two-compartment models across rich, medium, and sparse data. METHODS: One- and two-compartment models of the previous studies were used to simulate data in three scenarios: rich, medium, and sparse data...
May 21, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29779093/pharmacokinetics-of-the-novel-selective-non-steroidal-mineralocorticoid-receptor-antagonist-finerenone-in-healthy-volunteers-results-from-an-absolute-bioavailability-study-and-drug-drug-interaction-studies-in-vitro-and-in-vivo
#12
Roland Heinig, Michael Gerisch, Anna Engelen, Johannes Nagelschmitz, Stephanie Loewen
BACKGROUND AND OBJECTIVES: Finerenone is a selective, non-steroidal mineralocorticoid receptor antagonist. In vivo and in vitro studies were performed to assess absolute bioavailability of finerenone, the effect of metabolic enzyme inhibitors on the pharmacokinetics of finerenone and its metabolites, the quantitative contribution of the involved enzymes cytochrome P450 (CYP) 3A4 and CYP2C8 and the relevance of gut wall versus liver metabolism. METHODS: The pharmacokinetics, safety and tolerability of finerenone (1...
May 19, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29752643/effect-of-multiple-doses-of-omeprazole-on-the-pharmacokinetics-safety-and-tolerability-of-roxadustat-in-healthy-subjects
#13
Dorien Groenendaal-van de Meent, Martin den Adel, Jan van Dijk, Begona Barroso-Fernandez, Rachid El Galta, Georg Golor, Marloes Schaddelee
BACKGROUND AND OBJECTIVES: Roxadustat is an orally active hypoxia-inducible factor prolyl hydroxylase inhibitor for the treatment of anemia in chronic kidney disease. This study investigated the effect of multiple daily oral doses of omeprazole on the pharmacokinetics, safety, and tolerability of a single oral dose of roxadustat. METHODS: This phase 1, open-label, two-period, one-sequence, crossover study enrolled healthy subjects. During Period 1, subjects received a single oral dose of 100 mg roxadustat...
May 11, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29748821/absorption-distribution-metabolism-and-excretion-of-the-novel-helicase-primase-inhibitor-amenamevir-asp2151-in-rodents
#14
Yoshiaki Ohtsu, Yoko Susaki, Kiyoshi Noguchi
BACKGROUND AND OBJECTIVES: The helicase-primase inhibitor amenamevir (ASP2151) is a novel therapeutic agent which has been approved for the treatment of herpes zoster. The present study examined the pharmacokinetic profile of amenamevir in rodents and compared it with data from the literature of past and current established therapies (acyclovir and valaciclovir) to provide additional data to facilitate drug discovery and proper drug use. METHODS: In situ absorption, blood and plasma radioactivity concentrations, tissue distribution, and excretion were determined using liquid scintillation counting...
May 10, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29744741/effect-of-naltrexone-hydrochloride-on-cytochrome-p450-1a2-2c9-2d6-and-3a4-activity-in-human-liver-microsomes
#15
Haitham AlRabiah, Abdul Ahad, Gamal A E Mostafa, Fahad I Al-Jenoobi
BACKGROUND AND OBJECTIVE: Cytochrome P450 (CYP) 1A2, 2C9, 2D6, and 3A4 are the most important phase I drug-metabolizing enzymes in the liver, but there is a dearth of literature available on the effects of naltrexone hydrochloride on these major enzymes present in the human liver. Thus, in the present study, the effect of naltrexone hydrochloride on the activity of CYP1A2, 2C9, 2D6, and 3A4 using human liver microsomes (HLM) was investigated. METHODS: A selective probe for CYP1A2, 2C9, 2D6, and 3A4 was incubated with HLM with or without naltrexone hydrochloride...
May 9, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29725943/in-vitro-monitoring-of-the-mitochondrial-beta-oxidation-flux-of-palmitic-acid-and-investigation-of-its-pharmacological-alteration-by-therapeutics
#16
Renata Murgasova, Ester Tor Carreras, Julien Bourgailh
BACKGROUND AND OBJECTIVE: The present study was designed to validate the functional assay that enables rapid screening of therapeutic candidates for their effect on mitochondrial fatty acid oxidation. METHODS: The two whole-cell systems (tissue homogenates and hepatocytes) have been evaluated to monitor the total beta-oxidation flux of physiologically important 3 H-palmitic acid by measurement of tritiated water enrichment in incubations using UPLC coupled on-line to radioactivity monitoring and mass spectrometry...
May 3, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29721716/effect-of-gambogenic-acid-on-cytochrome-p450-1a2-2b1-and-2e1-and-constitutive-androstane-receptor-in-rats
#17
Jing Sun, Xiaozhu Tang, Qianqian Xu, Tao Ge, Daiyin Peng, Weidong Chen
BACKGROUND AND OBJECTIVES: Gambogenic acid (GNA), which possesses diverse antitumor activities both in vitro and in vivo, is regarded as a potential anticancer compound. Cytochrome P450 (CYP) enzymes play an important role in the metabolism of most xenobiotics; constitutive androstane receptor (CAR), a nuclear receptor that might be activated by xenobiotics and associated with the expression of some CYPs. In this study, we determined the effect of GNA on multiple rat liver CYP isoforms (CYP1A2, 2B1, and 2E1) and CAR as well as the potential of GNA to interact with co-administered drugs...
May 2, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29704095/pharmacokinetic-profiling-of-butylidenephthalide-and-alisol-b-in-danggui-shaoyao-san-in-rats
#18
Hui-Fei Wu, Xiang-Yu Wang, Ji-Feng Deng, Shi-Jian Quan, Qi Wang, Wei-Rong Li
BACKGROUND AND OBJECTIVE: Danggui-Shaoyao-San (DSS), a famous Chinese formula, has been widely used to treat gynecological disorders since ancient times and has recently showed efficacy in treating Alzheimer's disease. Butylidenephthalide (BDPH) and alisol B (ALI) are recognized as the primary active ingredients of DSS. The objectives of the present study were to evaluate the pharmacokinetic comparative study of BDPH and ALI in herbal extracts and their purified forms. METHOD: A sensitive and specific high-performance liquid chromatography tandem mass spectrometry (HPLC-MS/MS) methodology was developed to determine the concentration level of BDPH and ALI in rat plasma...
April 27, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29691732/impact-of-the-cyp3a5-1-allele-on-the-pharmacokinetics-of-tacrolimus-in-japanese-heart-transplant-patients
#19
Takaya Uno, Kyoichi Wada, Sachi Matsuda, Yuka Terada, Akira Oita, Atsushi Kawase, Mitsutaka Takada
BACKGROUND AND OBJECTIVE: Tacrolimus, a major immunosuppressant used after transplantation, is associated with large interindividual variation involving genetic polymorphisms in metabolic processes. A common variant of the cytochrome P450 (CYP) 3A5 gene, CYP3A5*3, affects blood concentrations of tacrolimus. However, tacrolimus pharmacokinetics at the early stage of transplantation have not been adequately studied in heart transplantation. We retrospectively examined the impact of the CYP3A5 genotype on tacrolimus pharmacokinetics at the early stage of heart transplantation...
April 24, 2018: European Journal of Drug Metabolism and Pharmacokinetics
https://www.readbyqxmd.com/read/29392568/effects-of-human-sulfotransferase-2a1-genetic-polymorphisms-3-on-the-sulfation-of-tibolone
#20
Ethan Miller, Munaf H Zalzala, Maryam S Abunnaja, Katsuhisa Kurogi, Yoichi Sakakibara, Masahito Suiko, Ming-Cheh Liu
BACKGROUND AND OBJECTIVES: Previous studies have demonstrated the metabolism of tibolone through sulfation, with the cytosolic sulfotransferase (SULT) SULT2A1 as the major responsible enzyme. The current study aimed to investigate how SULT2A1 genetic polymorphisms may affect the dehydroepiandrosterone (DHEA)- and tibolone-sulfating activity of SULT2A1. METHODS: Site-directed mutagenesis was employed to generate cDNAs encoding ten different SULT2A1 allozymes. Recombinant SULT2A1 allozymes were expressed in BL21 E...
August 2018: European Journal of Drug Metabolism and Pharmacokinetics
journal
journal
26770
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"